Tue Nov 26 19:30:00 UTC 2024: ## Amgen’s New Obesity Drug Shows Promising Weight Loss Results
**New York, NY** – Amgen announced Tuesday that its experimental obesity drug, MariTide, has shown significant weight loss in a Phase 2 clinical trial. Participants lost up to 20% of their body weight over a year. This monthly injection contrasts with the weekly injections required for currently available drugs like Wegovy and Ozempic, potentially offering a more convenient treatment option.
The trial involved nearly 600 participants, including both obese and overweight individuals and those with Type 2 diabetes. While the results are promising, Amgen emphasizes that MariTide still requires further clinical trials and FDA approval before market release. Pricing and a specific launch timeline have not yet been determined.
Dr. Jeffrey Flier, a Harvard diabetes and obesity researcher, described the results as “promising,” suggesting MariTide could become a significant competitor in the burgeoning obesity drug market. Detailed data from the trial will be released later in a peer-reviewed publication and presented at an upcoming medical meeting. The company released only top-line data to comply with SEC regulations. The impressive results follow the recent success of other weight-loss medications, signifying a potential shift in the treatment of obesity.
First Piper 